New immune cell shot targets Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests an experimental cell therapy called NK042 for people with advanced solid tumors that have not responded to standard treatments. The therapy uses specially prepared immune cells to attack the cancer. The main goals are to check safety and see if the tr…
Phase: PHASE1 • Sponsor: Shanghai NK Cell Technology Co., LTD • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC